Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience

作者
Metin Pehlivan,Nail Paksoy,Esra Aydın,Mert Başaran,Meltem Ekenel
出处
期刊:Medicine [Wolters Kluwer]
卷期号:102 (41): e35245-e35245 被引量:1
标识
DOI:10.1097/md.0000000000035245
摘要

Renal cell carcinoma is the 10th most common type of cancer, accounting for 3.7% of all cancers. Our study examines patients with metastatic renal cell carcinoma who received Axitinib or Nivolumab as second-line treatment. This study was designed as a retrospective analysis. Patients who received Axitinib or Nivolumab as second-line treatment for metastatic renal cell carcinoma at the Istanbul University Oncology Institute Medical Oncology outpatient clinic were included in the study. A total of 81 patients were included in the study, with a median follow-up period of 18.5 months (2-260 months). Of these patients, 29 (35.8%) received Axitinib as second-line treatment, while 52 (64.2%) received Nivolumab. The median duration of second-line treatment was 14 months (6-52) for Axitinib and 13.5 months (3-77) for Nivolumab. In our study, Nivolumab was found to have statistically better PFS and OS outcomes than Axitinib in male patients, patients diagnosed with metastatic disease, those with a favorable or intermediate International Metastatic Renal Cell Carcinoma Database Consortium risk score, patients diagnosed with metastatic disease or who developed metastasis within 12 months of diagnosis, those who developed metastasis ≥ 24 months after diagnosis, and patients with metastasis in a single organ. Both drugs are recommended as monotherapy for second-line and later treatments in the current NCCN guidelines for kidney cancers. Although there is no study in the literature showing that axitinib is more effective than nivolumab, nivolumab was found to be much more effective than axitinib in our study. Prospective studies with higher number of patients are needed on this subject.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
左左蕊完成签到,获得积分10
刚刚
刚刚
刚刚
1秒前
1秒前
OE完成签到,获得积分10
1秒前
1秒前
嘻嘻哈哈的应助被winwin采纳,获得10
1秒前
sss完成签到,获得积分10
2秒前
Evelina完成签到,获得积分10
2秒前
妮妮发布了新的文献求助10
2秒前
JanaL发布了新的文献求助10
3秒前
Lucas的应助被陶醉晓凡采纳,获得10
3秒前
3秒前
桐桐的应助被温暖砖头采纳,获得10
3秒前
JEJNKER完成签到,获得积分10
3秒前
充电宝的应助被肥肥大蘑菇采纳,获得10
4秒前
万能图书馆的应助被木木采纳,获得10
4秒前
英俊的铭的应助被梅梅美采纳,获得30
4秒前
4秒前
汉堡包的应助被Zz采纳,获得10
4秒前
5秒前
Jin发布了新的文献求助10
5秒前
什米发布了新的文献求助10
5秒前
6秒前
爱科研的赛的应助被崽崽采纳,获得20
6秒前
切尔茜发布了新的文献求助10
6秒前
核桃发布了新的文献求助20
6秒前
李健的小迷弟的应助被小臣采纳,获得10
6秒前
无心的蜗牛完成签到,获得积分10
6秒前
隐形曼青的应助被Maestro_S采纳,获得30
7秒前
7秒前
灵巧万言完成签到,获得积分10
7秒前
Joshua完成签到,获得积分10
7秒前
贪玩的筝发布了新的文献求助10
7秒前
cuize完成签到,获得积分10
7秒前
苏波完成签到,获得积分10
7秒前
情怀的应助被自然而然采纳,获得10
8秒前
8秒前
小蘑菇的应助被XXxx采纳,获得10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183046
求助须知:如何正确求助?哪些是违规求助? 9572370
关于积分的说明 21824411
捐赠科研通 7779694
什么是DOI,文献DOI怎么找? 3433792
关于科研通互助平台的介绍 2558024
邀请新用户注册赠送积分活动 2479971